Antifungals: what's in the pipeline |
| |
Authors: | Tkacz J S DiDomenico B |
| |
Affiliation: | Merck Research Laboratories, PO Box 2000/R80Y-215, Rahway, NJ 07065, USA. jan_tkacz@merck.com |
| |
Abstract: | The therapeutic landscape for mycotic infections is shifting. New generation azoles that are active against clinically relevant, drug-resistant fungal pathogens have improved bioavailability, half-lives and safety profiles. Acylated cyclic peptide inhibitors of beta(1,3)glucan synthesis with origins as fungal metabolites provide an alternative and highly-selective mode of action, targeting cell-wall biogenesis in important pathogens such as Candida and Aspergillus species. The development, in each structural class, of compounds that have advanced to late-stage clinical trials is summarized in this review. |
| |
Keywords: | |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|